U
15.40
0.34 (2.26%)
| Penutupan Terdahulu | 15.06 |
| Buka | 14.98 |
| Jumlah Dagangan | 2,625,203 |
| Purata Dagangan (3B) | 1,911,003 |
| Modal Pasaran | 750,643,712 |
| Harga / Pendapatan (P/E Ke hadapan) | 27.93 |
| Harga / Jualan (P/S) | 28.74 |
| Harga / Buku (P/B) | 14.83 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Feb 2025 - 1 Mar 2025 |
| Margin Operasi (TTM) | -1,776.91% |
| EPS Cair (TTM) | -4.95 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 62.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 889.83% |
| Nisbah Semasa (MRQ) | 6.51 |
| Aliran Tunai Operasi (OCF TTM) | -179.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -125.18 M |
| Pulangan Atas Aset (ROA TTM) | -16.62% |
| Pulangan Atas Ekuiti (ROE TTM) | -147.57% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | uniQure N.V. | Menaik | Menaik |
AISkor Stockmoo
1.1
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.13 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.24% |
| % Dimiliki oleh Institusi | 89.28% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 58.00 (Cantor Fitzgerald, 276.62%) | Beli |
| Median | 28.50 (85.07%) | |
| Rendah | 20.00 (Mizuho, 29.87%) | Pegang |
| 20.00 (Goldman Sachs, 29.87%) | Pegang | |
| 20.00 (RBC Capital, 29.87%) | Beli | |
| Purata | 33.88 (120.00%) | |
| Jumlah | 6 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 15.64 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 19 Dec 2024 | 20.00 (29.87%) | Pegang | 15.47 |
| Stifel | 16 Dec 2024 | 32.00 (107.79%) | Beli | 17.40 |
| Goldman Sachs | 12 Dec 2024 | 20.00 (29.87%) | Pegang | 15.06 |
| 06 Nov 2024 | 9.00 (-41.56%) | Pegang | 7.16 | |
| Leerink Partners | 11 Dec 2024 | 44.00 (185.71%) | Beli | 15.65 |
| RBC Capital | 11 Dec 2024 | 20.00 (29.87%) | Beli | 15.65 |
| 06 Nov 2024 | 14.00 (-9.09%) | Beli | 7.16 | |
| Cantor Fitzgerald | 10 Dec 2024 | 58.00 (276.62%) | Beli | 15.30 |
| 06 Nov 2024 | 28.00 (81.82%) | Beli | 7.16 | |
| HC Wainwright & Co. | 10 Dec 2024 | 25.00 (62.34%) | Beli | 15.30 |
| 06 Nov 2024 | 25.00 (62.34%) | Beli | 7.16 | |
| Raymond James | 10 Dec 2024 | 52.00 (237.66%) | Beli | 15.30 |
| 10 Oct 2024 | 20.00 (29.87%) | Beli | 5.42 | |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |